Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Radiopharm Theranostics Limited - Sponsored ADR (RADX) had Return on Tangible Equity of 359.58% for the most recently reported fiscal year, ending 2026-06-30.
| Income Statement Financials | |
$1.88M |
|
$-38.65M |
|
$1.70M |
|
$0.18M |
|
$40.42M |
|
$-38.54M |
|
$-0.08M |
|
$-38.62M |
|
$-38.62M |
|
$-38.65M |
|
$-38.65M |
|
$-38.65M |
|
$-38.65M |
|
$-38.54M |
|
$-36.70M |
|
10.24M |
|
10.24M |
|
$-3.63 |
|
$-3.63 |
|
| Balance Sheet Financials | |
$14.88M |
|
$0.03M |
|
$25.93M |
|
$40.81M |
|
$12.83M |
|
-- |
|
$12.84M |
|
$25.66M |
|
$15.15M |
|
$-10.75M |
|
$15.15M |
|
11.81M |
|
| Cash Flow Statement Financials | |
$-35.82M |
|
$-3.68M |
|
$22.65M |
|
$19.76M |
|
$2.81M |
|
$-16.95M |
|
$1.63M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.16 |
|
-- |
|
-- |
|
-- |
|
-- |
|
9.52% |
|
-2051.52% |
|
-2051.52% |
|
-1953.75% |
|
-2055.58% |
|
-2057.54% |
|
$-35.82M |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
-- |
|
0.16 |
|
2300.78 |
|
-255.11% |
|
|
Return on Tangible Equity |
359.58% |
-94.71% |
|
-255.11% |
|
$1.28 |
|
$-3.50 |
|
$-3.50 |
|